Skip to main content

WPI 2245 Pill - brown oval, 21mm

Pill with imprint WPI 2245 is Brown, Oval and has been identified as Mesalamine Delayed-Release 1.2 g. It is supplied by Actavis Pharma, Inc.

Mesalamine is used in the treatment of Crohn's Disease, Maintenance; Inflammatory Bowel Disease; Ulcerative Colitis, Active; Ulcerative Colitis, Maintenance; Ulcerative Colitis and belongs to the drug class 5-aminosalicylates. excluding Asacol and Asacol HD: There is no proven risk in humans during pregnancy. Asacol and Asacol HD: Risk cannot be ruled out during pregnancy. Mesalamine 1.2 g is not a controlled substance under the Controlled Substances Act (CSA).

Images for WPI 2245

Mesalamine delayed-release 1.2 g WPI 2245
Mesalamine delayed-release 1.2 g WPI 2245

Mesalamine Delayed-Release

Imprint
WPI 2245
Strength
1.2 g
Color
Brown
Size
21.00 mm
Shape
Oval
Availability
Prescription only
Drug Class
5-aminosalicylates
Pregnancy Category
B - No proven risk in humans - excluding Asacol and Asacol HD, C - Risk cannot be ruled out - Asacol and Asacol HD
CSA Schedule
Not a controlled drug
Labeler / Supplier
Actavis Pharma, Inc.
National Drug Code (NDC)
00591-2245
Inactive Ingredients
copovidone, silicon dioxide, hypromellose 2910 (6 mPa.s), magnesium stearate, methacrylic acid - methyl methacrylate copolymer (1:1), methacrylic acid - methyl methacrylate copolymer (1:2), ferrosoferric oxide, ferric oxide red, ferric oxide yellow, microcrystalline cellulose, povidone k90, polyethylene glycol 400, polyethylene glycol 3350, polyethylene glycol 8000, propylene glycol, sodium starch glycolate type A potato, magnesium silicate, titanium dioxide, triethyl citrate

Note: Inactive ingredients may vary.

Drug Uses Add to Drug List Print

Get help with Imprint Code FAQs.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer